Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

• ClinicalTrials.gov Identifier: NCT00115570
• Recruitment Status: Completed
• First Posted: June 24, 2005
• Last Update Posted: May 20, 2016
• Sponsor: Sanofi
• Information provided by (Responsible Party): Sanofi

Study Description

Brief Summary:

The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.

Condition or disease	Intervention/treatment	Phase
Diabetes Mellitus, Insulin-Dependent	Drug: Insulin glulisine; Drug: insulin lispro; Drug: insulin glargine; Drug: NPH insulin	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 572 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Efficacy and Safety of Insulin Glulisine Compared With Insulin Lispro in Children and Adolescents With Type 1 Diabetes Mellitus: A 26 Week, Multicenter, Open, Parallel Clinical Trial
• Study Start Date: April 2005
• Actual Primary Completion Date: November 2006
• Actual Study Completion Date: November 2006

Arms and Interventions

Arm	Intervention/treatment
Experimental: Insulin Glulisine; Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks	Drug: Insulin glulisine; Subcutaneous injection; Other Name: apidra; Drug: insulin glargine; Subcutaneous injection once daily; Drug: NPH insulin; subcutaneous injection twice daily
Active Comparator: Insulin Lispro; Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks	Drug: insulin lispro; Subcutaneous injection; Drug: insulin glargine; Subcutaneous injection once daily; Drug: NPH insulin; subcutaneous injection twice daily

Outcome Measures

Primary Outcome Measures :

1. Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpoint [ Time Frame: week 26 or last observed treatment ]

Secondary Outcome Measures :

1. Change from Baseline in GHb at weeks 12 and 26 [ Time Frame: weeks 12 and 26 ]
2. Change from Baseline in Self-monitored glucose parameters [ Time Frame: weeks 4, 12, 18, 26, and endpoint; ]
3. Incidence of Symptomatic hypoglycemia [ Time Frame: first dose of study up to last dose ]
4. Change from Baseline in basal insulin dose [ Time Frame: week 4, 12, 18, 26, and endpoint; ]

Eligibility Criteria

• Ages Eligible for Study: 4 Years to 17 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Girls/boys, 4-17 years, inclusive;
• Girls not yet of childbearing potential or, if sexually active, agree to use reliable medically accepted contraceptive measure during study;
• Type 1 diabetes mellitus established in medical history: for example, but not limited to, clear signs of insulinopenia (polyuria, polydipsia, polyphagia, weight loss, ketonuria, ketoacidosis); or glutamic acid decarboxylase (GAD) antibody indicative of type 1 diabetes measured at any time before study; or requiring continuous insulin therapy from time of diagnosis;
• Onset of diabetes at least 1 year prior to visit 1 (V1) of study;
• Uninterrupted insulin therapy for at least 1 year before V1 of study;
• At V1, on stable insulin regimen of either NPH or insulin glargine as basal insulin and willing to have multiple daily injections of insulin;
• Glycated hemoglobin at V1 between ≥ 6.0 and ≤11.0 %;
• Ability/willingness to do blood glucose monitoring using sponsor-provided glucometer and subject diary.

Exclusion Criteria:

• Active proliferative diabetic retinopathy, defined by application of focal or panretinal photocoagulation or vitrectomy, 6 months before V1, or any other unstable/rapidly progressing retinopathy requiring surgical treatment (including laser photocoagulation) during study;
• Diabetes other than type 1 diabetes mellitus;
• Pregnancy (positive pregnancy blood test at V1) or breastfeeding;
• Pancreatectomized subjects;
• Subjects who have had pancreas and/or islet cell transplants;
• Treatment with any anti-diabetic oral agent at any time from diabetes diagnosis;
• Treatment with systemic corticosteroids in last month before V1;
• Subjects on pump therapy during last 2 months before V1;
• Subjects requiring excessively high doses of insulin ("resistant" patients), for example, but not limited to, subjects receiving over 150 IU per day;
• Likelihood of needing treatment during study period with drugs not permitted by protocol
• Treatment with any investigational drug in last month before V1;
• History of primary seizure disorders;
• History of severe hypoglycemic episode accompanied by seizure and/or coma or diabetic ketoacidosis leading to hospitalization, or to care in emergency ward, 3 months prior to V1;
• History of hypoglycemia unawareness;
• History of hypersensitivity to insulin or insulin analogs or any of the excipients in insulin glulisine formulation or any of the excipients in other study insulin preparations formulations;
• Clinically relevant hepatic, neurologic, endocrine, active cancer, or other major systemic disease making implementation of protocol or interpretation of study results difficult and would, in the opinion of the investigator, preclude safe participation of subject in protocol;
• History of cardiac abnormalities and/or cardiovascular disorders;
• History of drug/alcohol abuse;
• Impaired hepatic function shown by, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than twice the normal upper limit for age at V1;
• Impaired renal function shown by, but not limited to, serum creatinine greater than 1.5 times upper limit for age at V1;
• Non fasting triglyceride level of >500 mg/dL (5.7 mmol/L) at V1;
• Parent/legally authorized representative unable to understand nature, scope, possible consequences of study;
• Parent/legally authorized representative unable to read/write;
• Subjects unlikely to comply with protocol, e.g. inability/unwillingness to participate in adequate training, uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing study;
• Children/relatives of employee of sponsor or of sponsor representatives;
• Children or relatives of investigator, any sub-investigator, research assistant, pharmacist, study coordinator or other staff directly involved in conduct of protocol;
• Subjects who have previously been treated with insulin glulisine.

Contacts and Locations

Locations

United States, Pennsylvania

Childrens Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213

Sponsors and Collaborators

Sanofi

Investigators

• Principal Investigator: Dr Arethi PHILOTHEOU; UCT Diabetes Clinical Trials Unit - Faculty of Health Sciences - South-Africa

More Information

• Responsible Party: Sanofi
• ClinicalTrials.gov Identifier: NCT00115570
• Other Study ID Numbers: EFC6096; HMR 1964
• First Posted: June 24, 2005
• Last Update Posted: May 20, 2016
• Last Verified: May 2016

Keywords provided by Sanofi:

Diabetes,Insulin-Dependent, pediatric,rapid acting injection

Additional relevant MeSH terms:

Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Insulin; Insulin, Globin Zinc; Insulin Glargine; Insulin Lispro; Insulin glulisine; Insulin, Isophane; Isophane Insulin, Human; Isophane insulin, beef; Hypoglycemic Agents; Physiological Effects of Drugs